Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2R | P25116 | 10/20 | 0.56 |
| ▸ | CNR1 | P21554 | 1/20 | 0.56 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.56 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.35 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3753214 | 0.94 | F2R (0.49) | F2RCNR1TMEM97CHRM2CHRM4 | |
| SCHEMBL3760747 | 0.92 | F2R (0.60) | F2RCNR1TMEM97CHRM2CHRM4 | |
| SCHEMBL3755818 | 0.91 | F2R (0.70) | F2RCNR1TMEM97CHRM2CHRM4 | |
| SCHEMBL3760972 | 0.90 | F2R (0.44) | F2RCNR1TMEM97CHRM2CHRM4 | |
| SCHEMBL3798403 | 0.90 | F2R (0.49) | F2RCNR1TMEM97CHRM2CHRM4 | |
| SCHEMBL3757407 | 0.90 | F2R (0.55) | F2RCNR1TMEM97CHRM2CHRM4 | |
| SCHEMBL1581294 | 0.90 | F2R (0.43) | F2RCNR1TMEM97CHRM2CHRM4 | |
| SCHEMBL3766060 | 0.89 | F2R (0.59) | F2RCNR1TMEM97LMNAGAA | |
| SCHEMBL3760958 | 0.88 | F2R (0.43) | F2RCNR1TMEM97CHRM2CHRM4 | |
| SCHEMBL640874 | 0.88 | F2R (0.51) | F2RCNR1TMEM97LMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130252948-A1 | Substituted piperidines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-09-26 | — | — | US | disclosed |
| US-8440657-B2 | Substituted piperidines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-05-14 | — | — | US | disclosed |
| US-8440657-B2 | Substituted piperidines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-05-14 | — | — | US | disclosed |
| US-8440657-B2 | Substituted piperidines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-05-14 | — | — | US | disclosed |
| US-8202862-B2 | Substituted piperidines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-06-19 | — | — | US | disclosed |
| US-8202862-B2 | Substituted piperidines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-06-19 | — | — | US | disclosed |
| US-8202862-B2 | Substituted piperidines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-06-19 | — | — | US | disclosed |
| US-20120135985-A1 | Substituted piperidines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-05-31 | — | — | US | disclosed |
| US-20120135985-A1 | Substituted piperidines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-05-31 | — | — | US | disclosed |
| US-20120135985-A1 | Substituted piperidines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-05-31 | — | — | US | disclosed |
| WO-2010136138-A1 | SUBSTITUTED PIPERIDINES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-12-02 | — | — | WO | disclosed |
| WO-2010136138-A1 | SUBSTITUTED PIPERIDINES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-12-02 | — | — | WO | disclosed |
| US-20100305111-A1 | SUBSTITUTED PIPERIDINES | Bayer Schering Pharma (DE) | 2010-12-02 | — | — | US | disclosed |
| US-20100305111-A1 | SUBSTITUTED PIPERIDINES | Bayer Schering Pharma (DE) | 2010-12-02 | — | — | US | disclosed |
| US-20100305111-A1 | SUBSTITUTED PIPERIDINES | Bayer Schering Pharma (DE) | 2010-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305111-A1 | SUBSTITUTED PIPERIDINES | VHL, PIR, PTGIS | F2R 1245/4885CNR1 538/4885TMEM97 1046/4885 |
| US-20120135985-A1 | Substituted piperidines | VHL, PIR, PTGIS | F2R 1245/4885CNR1 538/4885TMEM97 1046/4885 |
| US-20130252948-A1 | Substituted piperidines | VHL, PIR, PTGIS | F2R 1245/4885CNR1 538/4885TMEM97 1046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.